1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl- manufacturers
- SR-318
-
- $53.00
-
2026-07-27
- CAS:2413286-32-3
- Purity: 99.74%
- Supply Ability: 10g
- SR-318
-
- $53.00
-
2026-07-27
- CAS:2413286-32-3
- Purity: 99.74%
- Supply Ability: 10g
|
| | 1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl- Basic information |
| Product Name: | 1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl- | | Synonyms: | 1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl-;SR-318;anti-inflammatory,SR 318,TNFR,anti-cancer,p38 MAPK,Inhibitor,inhibit,whole,TNF Receptor,SR-318,SR318,p38α/β,Tumor Necrosis Factor Receptor,blood;SR-318, 10 mM in DMSO;5-Amino-N-(4-((3-cyclohexylpropyl)carbamoyl)benzyl)-1-phenyl-1H-pyrazole-4-carboxamide | | CAS: | 2413286-32-3 | | MF: | C27H33N5O2 | | MW: | 459.58 | | EINECS: | | | Product Categories: | | | Mol File: | 2413286-32-3.mol | ![1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl- Structure](CAS/20200611/GIF/2413286-32-3.gif) |
| | 1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl- Chemical Properties |
| Boiling point | 732.0±60.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO:40.0(Max Conc. mg/mL);87.03(Max Conc. mM) | | form | A solid | | pka | 13.10±0.46(Predicted) | | color | White to off-white | | InChIKey | HXNUFFCHRIWTRZ-UHFFFAOYSA-N | | SMILES | NC1=C(C(NCC2=CC=C(C(NCCCC3CCCCC3)=O)C=C2)=O)C=NN1C4=CC=CC=C4 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | 1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl- Usage And Synthesis |
| Uses | SR-318 is a potent and highly selective p38 MAPK inhibitor with IC50s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC50 of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity[1]. | | Biological Activity | SR-318 is a potent and selective type-II inhibitor th at targets p38α/β in an inactive DFG-out conformation with good kinome selectivity (p38α/β IC50 = 5/39 nM by radiometric kinase assay). SR-318 selectively inhibits p38α/β by cell-based NanoBRET assay (IC50 = 3.7 nM/p38α, 10 nM/p38β, 0.91 μM/ZAK, ≥3 μM/DDR1, DDR2, KIT, MYLK4, RSK4) and effectively blocks LPS-induced TNF-α release in human whole blood (IC50 = 283 nM). SR-321 is an inactive structural analog and the recommended negative control compound. | | IC 50 | p38α: 5 nM (IC50); p38β: 32 nM (IC50) | | References | [1] Rhm S, et al. Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors. J Med Chem. 2019 Dec 12;62(23):10757-10782. DOI:10.1021/acs.jmedchem.9b01227 |
| | 1H-Pyrazole-4-carboxamide, 5-amino-N-[[4-[[(3-cyclohexylpropyl)amino]carbonyl]phenyl]methyl]-1-phenyl- Preparation Products And Raw materials |
|